MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 528097 | Name: Pergolide mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pergolide mesylate is a long-acting dopamine agonist which has been used to treat Parkinson disease and hyperprolactinemia but withdrawn from some markets due to potential for heart valve diseases.

Chemical Structure

Pergolide mesylate
CAS#66104-23-2

Theoretical Analysis

MedKoo Cat#: 528097

Name: Pergolide mesylate

CAS#: 66104-23-2

Chemical Formula: C20H30N2O3S2

Exact Mass: 410.1698

Molecular Weight: 410.59

Elemental Analysis: C, 58.51; H, 7.36; N, 6.82; O, 11.69; S, 15.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pergolide mesylate
IUPAC/Chemical Name
8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate
InChi Key
UWCVGPLTGZWHGS-ZORIOUSZSA-N
InChi Code
InChI=1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1
SMILES Code
[H][C@@]1(N(CCC)C[C@H](CSC)C[C@@]12[H])CC3=CNC4=C3C2=CC=C4.CS(=O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 410.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Volochanskyi O, Švecová M, Prokopec V. Detection and identification of medically important alkaloids using the surface-enhanced Raman scattering spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Jan 15;207:143-149. doi: 10.1016/j.saa.2018.09.009. Epub 2018 Sep 9. PubMed PMID: 30223248. 2: Kienzle E, Bockhorni T. [Nutrition of horses with equine pituitary pars intermedia dysfunction ("Cushing's syndrome") treated with pergolid - A field study]. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2018 Aug;46(4):249-256. doi: 10.15653/tpg-170574. Epub 2018 Aug 24. German. PubMed PMID: 30142655. 3: Kon T, Ueno T, Haga R, Tomiyama M. The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. Brain Behav. 2018 Aug;8(8):e01036. doi: 10.1002/brb3.1036. Epub 2018 Jun 29. PubMed PMID: 29956879; PubMed Central PMCID: PMC6085905. 4: Shotton JCR, Justice WSM, Salguero FJ, Stevens A, Bacci B. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII). J Zoo Wildl Med. 2018 Jun;49(2):404-411. doi: 10.1638/2017-0149.1. PubMed PMID: 29900762. 5: Secombe CJ, Bailey SR, de Laat MA, Hughes KJ, Stewart AJ, Sonis JM, Tan R. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group. Aust Vet J. 2018 Jul;96(7):233-242. doi: 10.1111/avj.12716. Epub 2018 Jun 3. Review. PubMed PMID: 29862508. 6: Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, Winkelman JW, Trenkwalder C, Sampaio C. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)(§). Mov Disord. 2018 Jul;33(7):1077-1091. doi: 10.1002/mds.27260. Epub 2018 May 14. Review. PubMed PMID: 29756335. 7: Christen G, Gerber V, van der Kolk JH, Frey CF, Fouché N. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide. Vet J. 2018 May;235:60-62. doi: 10.1016/j.tvjl.2018.03.007. Epub 2018 Mar 23. PubMed PMID: 29704940. 8: Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Review. PubMed PMID: 29570866. 9: Mogwitz S, Buse J, Wolff N, Roessner V. Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents. ACS Chem Neurosci. 2018 Apr 18;9(4):651-672. doi: 10.1021/acschemneuro.7b00460. Epub 2018 Mar 16. PubMed PMID: 29498507. 10: Ferguson LB, Ozburn AR, Ponomarev I, Metten P, Reilly M, Crabbe JC, Harris RA, Mayfield RD. Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice. Neuropsychopharmacology. 2018 May;43(6):1257-1266. doi: 10.1038/npp.2017.301. Epub 2017 Dec 18. PubMed PMID: 29251283; PubMed Central PMCID: PMC5916369. 11: Carmalt JL, Waldner CL, Allen AL. Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence. Can J Vet Res. 2017 Oct;81(4):261-269. PubMed PMID: 29081583; PubMed Central PMCID: PMC5644449. 12: Li BD, Bi ZY, Liu JF, Si WJ, Shi QQ, Xue LP, Bai J. Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison. CNS Neurosci Ther. 2017 Oct;23(10):827-842. doi: 10.1111/cns.12727. Epub 2017 Sep 4. PubMed PMID: 28872217. 13: Jean PA, Sloter ED, Plotzke KP. Effects of chronic exposure to octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane in the aging female Fischer 344 rat. Toxicol Lett. 2017 Oct 20;279 Suppl 1:54-74. doi: 10.1016/j.toxlet.2017.08.016. Epub 2017 Aug 23. PubMed PMID: 28842205. 14: Kurian MA. SLC6A3-Related Dopamine Transporter Deficiency Syndrome. 2017 Jul 27. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK442323/ PubMed PMID: 28749637. 15: Randleff-Rasmussen PK, Mosca M, Knoerr F, Pin D, Desjardins I. Successful medical treatment of an Aspergillus terreus mycetoma of the nostril/lip in a 16-year-old Fjord pony gelding with pituitary pars intermedia dysfunction. Vet Dermatol. 2017 Dec;28(6):629-e155. doi: 10.1111/vde.12471. Epub 2017 Jul 23. PubMed PMID: 28736852. 16: Levite M, Marino F, Cosentino M. Dopamine, T cells and multiple sclerosis (MS). J Neural Transm (Vienna). 2017 May;124(5):525-542. doi: 10.1007/s00702-016-1640-4. Epub 2017 Mar 10. Review. PubMed PMID: 28283756. 17: Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci. 2017 Mar 4;18(3). pii: E551. doi: 10.3390/ijms18030551. Review. PubMed PMID: 28273839; PubMed Central PMCID: PMC5372567. 18: Durham AE. Therapeutics for Equine Endocrine Disorders. Vet Clin North Am Equine Pract. 2017 Apr;33(1):127-139. doi: 10.1016/j.cveq.2016.11.003. Epub 2017 Feb 9. Review. PubMed PMID: 28190613. 19: Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. Eur J Clin Pharmacol. 2017 Jan;73(1):99-103. doi: 10.1007/s00228-016-2142-x. Epub 2016 Oct 27. PubMed PMID: 27796464. 20: Hollingworth SA, McGuire TM, Pache D, Eadie MJ. Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. Drugs Real World Outcomes. 2015 Sep;2(3):199-203. PubMed PMID: 27747566; PubMed Central PMCID: PMC4883210.